QUEBEC, Dec. 19, 2025 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription drugs ...

The Company announces that the Board of Directors has approved the granting of 2,948,056 stock options to directors and a consultant of the Company. Of the options, 2,798,056 were granted to directors ...

QUÉBEC, Dec. 4, 2025 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription ...

"Our year-end results reflect a company that is financially disciplined, debt-free, and strategically positioned for the next phase of value creation. With this strong foundation, we are intensifying ...

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult ...

As more people look for natural health treatments, they look at the true journey of the products they plan to apply to their skin. Right from how sustainable the company is to where the ingredients ...

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to ...

QUEBEC CITY--(BUSINESS WIRE)-- Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to ...